MRK·Merck & Co., Inc.

Wells Fargo has upgraded Merck to Overweight with a $150 price target, driven by the significant potential of its Sac-TMT drug, which analysts believe could become a best-in-class TROP2 ADC and potentially replace chemotherapy across various cancer types. This optimistic outlook on Sac-TMT's future market impact contrasts with recent news of layoffs at a Gardasil production facility, stemming from a notable decline in vaccine sales, particularly in China. Meanwhile, institutional investors are showing mixed signals, with Gotham Asset Management significantly increasing its stake by 23.6%, indicating growing confidence, while Fayez Sarofim & Co. reduced its holdings by 8.2% in the third quarter, suggesting portfolio rebalancing. These shifts in institutional sentiment occur as Merck continues to highlight its commitment to advancing cardio-pulmonary research, with new clinical data on investigational treatments for hypercholesterolemia and pulmonary hypertension set to be presented at the American College of Cardiology's ACC.26 conference. Investors will be watching the data released from these presentations for potential implications on future pipeline progression and market positioning. Additionally, Merck's strong financial fundamentals support a consistent dividend yield, positioning it as a reliable income stock.